Akèy › Myelofibroz › New York
Etid klinik pou Myelofibroz nan New York
21 etid pou Myelofibroz ap chèche patisipan nan sit nan New York.
Vil nan New York
Tèks ofisyèl etid la (Anglè)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical Center, New York
- ak 1 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- New York Oncology Hematology P C, Albany
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07357727A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07623161A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- NYP/Weill Cornell Medical Center, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06661915Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Montefiore, New York
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05320198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering, New York
- Icahn School of Medicine at Mount Sinai, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06343805A Telehealth Advance Care Planning Intervention
- University of Rochester, Rochester
Ap rekrite
Laj 60 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT05875805A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Icahn School of Medicine At Mount Sinai, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07008118A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center, New York
- ak 1 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06773195Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Memorial Sloan Kettering Cancer Center, New York
- Mount Sinai School of Medicine, New York
- Weill Cornell Medicine, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07441694Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
- Wilmot Cancer Institute, University of Rochester, Rochester
Ap rekriteFaz 1 bonè
Laj 18 a 75 · Tout sèks · Mizajou Jun 3, 2026 · NCT03964506Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
- Roswell Park Cancer Institute, Buffalo
- Ruttenberg Treatment Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT05835466Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- GSK Investigational Site, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 20, 2026 · NCT06517875A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Icahn School of Medicine At Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Memorial Sloan Kettering, New York
Ap rekriteFaz 2
Laj 18 a 66 · Tout sèks · Mizajou Mar 17, 2026 · NCT06859424A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Weill Cornell Medicine NewYork-Presbyterian, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 12, 2026 · NCT05980806MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 23, 2026 · NCT07362225MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
- Ruttenberg Treatment Center, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 17, 2025 · NCT06541249SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Buffalo
- Massive Bio SYNERGY-AI site, Hempstead
- Massive Bio SYNERGY-AI site, Manhasset
- ak 2 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Brookdale University Hospital and Medical Center, Brooklyn
- Cayuga Cancer Center, Ithaca
- Northwell Health, R.J. Zuckerberg Cancer Center, Lake Success
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT06479135Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- Columbia University, New York
- Montefiore Einstein Cancer Center, The Bronx
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2025 · NCT05423691Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.